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Background
It is well known that the virological response after pegy-
lated interferon (IFN) treatment in chronic HBV hepatitis
is less than 50%. The main advantage of IFN is the finite
duration of therapy. A response guided therapy in this
situation would be very important in order to recognize
earlier the patients with poor response. Unfortunately,
Romanian guidelines for HBV hepatitis treatment do not
include a response guided therapy and IFN-based
regimens are recommended for one year. Objective: To
analyze the factors correlated with the virological response
to IFN in chronic HBV hepatitis.
Methods
We made a retrospective analysis of the HBV chronically
infected patients treated with IFN, monitored in Third
Department of Matei Bals Institute. Patients were divided
in two groups: group 1, with virological response and
group 2, without virological response. The virological
response to IFN is defined as viral load <2000 IU/mL
after one year of follow-up (according to EASL guideline).
The inclusion criteria in our study: HBV infected patients
treated one year with IFN who have finished the therapy
for more than one year.
Results
Fifty-six patients met the inclusion criteria. 23 patients
achieved virological response (group 1) and 33 patients
didn’t respond to IFN and were subsequently treated with
entecavir (group 2). Mean age was similar in both groups:
38.4 vs. 38.54 year-old. Sex ratio was M:F=1:1.8 in group 1
and M:F=3.125:1 in group 2; therefore, male gender repre-
sents a risk factor for non-response to IFN – RR=2.18
(1.21;3.94). The rate of positive HBeAg was 21.73% in
group 1 and 24.24% in group 2. The presence of HBeAg
was not statistically correlated with poor response to IFN:
RR=0.92 (0.42; 1.99), but the HBe seroconversion during
IFN therapy was a very good predictor for response: RR=6
(1; 35.9), p=0.005. The starting level of viral load below
106 IU/mL was considered a predictive factor for a good
response to IFN – RR=1.43 (1.02; 2.27), p=0.04. Increased
ALT was not associated with a good response to IFN
(despite literature data), RR=1.16 (0.81; 1.66), p=0.55.
We point out that our patients were not systematically
evaluated regarding the viral load level after three and six
months of therapy.
Conclusion
The use of IFN in selected patients can improve the vir-
ological response. Female gender, HBe seroconversion
during therapy and the viral load below 106 represent
good predictors to response. Positive HBeAg and
increased ALT at baseline were not associated with viro-
logical response.
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